412 related articles for article (PubMed ID: 37425044)
1. Light-responsive nanomedicine for cancer immunotherapy.
Kang W; Liu Y; Wang W
Acta Pharm Sin B; 2023 Jun; 13(6):2346-2368. PubMed ID: 37425044
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine-based tumor photothermal therapy synergized immunotherapy.
Shang T; Yu X; Han S; Yang B
Biomater Sci; 2020 Oct; 8(19):5241-5259. PubMed ID: 32996922
[TBL] [Abstract][Full Text] [Related]
4. Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy.
Boone CE; Wang L; Gautam A; Newton IG; Steinmetz NF
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Jan; 14(1):e1739. PubMed ID: 34296535
[TBL] [Abstract][Full Text] [Related]
5. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma.
Xu J; Zheng Q; Cheng X; Hu S; Zhang C; Zhou X; Sun P; Wang W; Su Z; Zou T; Song Z; Xia Y; Yi X; Gao Y
J Nanobiotechnology; 2021 Oct; 19(1):355. PubMed ID: 34717654
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Microenvironment-Responsive Nanomedicine for Enhanced Cancer Immunotherapy.
Peng S; Xiao F; Chen M; Gao H
Adv Sci (Weinh); 2022 Jan; 9(1):e2103836. PubMed ID: 34796689
[TBL] [Abstract][Full Text] [Related]
7. Polysaccharide-Based Stimulus-Responsive Nanomedicines for Combination Cancer Immunotherapy.
Li Q; Liu X; Yan C; Zhao B; Zhao Y; Yang L; Shi M; Yu H; Li X; Luo K
Small; 2023 Jun; 19(23):e2206211. PubMed ID: 36890780
[TBL] [Abstract][Full Text] [Related]
8. Emerging Nano-/Microapproaches for Cancer Immunotherapy.
Mi Y; Hagan CT; Vincent BG; Wang AZ
Adv Sci (Weinh); 2019 Mar; 6(6):1801847. PubMed ID: 30937265
[TBL] [Abstract][Full Text] [Related]
9. Nanotechnology platforms for cancer immunotherapy.
Yang Z; Ma Y; Zhao H; Yuan Y; Kim BYS
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Mar; 12(2):e1590. PubMed ID: 31696664
[TBL] [Abstract][Full Text] [Related]
10. Nano Drug Delivery System for Tumor Immunotherapy: Next-Generation Therapeutics.
Zhou L; Zou M; Xu Y; Lin P; Lei C; Xia X
Front Oncol; 2022; 12():864301. PubMed ID: 35664731
[TBL] [Abstract][Full Text] [Related]
11. Vaccine-like nanomedicine for cancer immunotherapy.
Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions.
Liu J; Zhang R; Xu ZP
Small; 2019 Aug; 15(32):e1900262. PubMed ID: 30908864
[TBL] [Abstract][Full Text] [Related]
13. Delivering safer immunotherapies for cancer.
Milling L; Zhang Y; Irvine DJ
Adv Drug Deliv Rev; 2017 May; 114():79-101. PubMed ID: 28545888
[TBL] [Abstract][Full Text] [Related]
14. Targeted NIR-responsive theranostic immuno-nanomedicine combined TLR7 agonist with immune checkpoint blockade for effective cancer photothermal immunotherapy.
Yasothamani V; Vivek R
J Mater Chem B; 2022 Aug; 10(33):6392-6403. PubMed ID: 35971846
[TBL] [Abstract][Full Text] [Related]
15. Enhancing Cancer Immunotherapeutic Efficacy with Sonotheranostic Strategies.
Zafar A; Hasan M; Tariq T; Dai Z
Bioconjug Chem; 2022 Jun; 33(6):1011-1034. PubMed ID: 34793138
[TBL] [Abstract][Full Text] [Related]
16. Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective.
Allegra A; Gioacchino MD; Tonacci A; Petrarca C; Gangemi S
Nanomaterials (Basel); 2021 Oct; 11(11):. PubMed ID: 34835555
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicines Targeting the Tumor Microenvironment.
Tong R; Langer R
Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084
[TBL] [Abstract][Full Text] [Related]
18. Advances in engineering local drug delivery systems for cancer immunotherapy.
Abdou P; Wang Z; Chen Q; Chan A; Zhou DR; Gunadhi V; Gu Z
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Sep; 12(5):e1632. PubMed ID: 32255276
[TBL] [Abstract][Full Text] [Related]
19. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment.
Sun B; Hyun H; Li LT; Wang AZ
Acta Pharmacol Sin; 2020 Jul; 41(7):970-985. PubMed ID: 32424240
[TBL] [Abstract][Full Text] [Related]
20. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
Yang J; Zhang C
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
